EGM
DNLI icon

Engineers Gate Manager’s Denali Therapeutics DNLI Stock Holding History

Engineers Gate Manager’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.48M Buy
57,430
+41,320
+256% +$849K 0.02% 855
2026
Q1 		$309K Buy
+16,110
New +$321K ﹤0.01% 1693
2025
Q4 		– Sell
-69,216
Closed -$1.01M – 2195
2025
Q3 		$1.01M Sell
69,216
-46,885
-40% -$674K 0.01% 1149
2025
Q2 		$1.62M Buy
116,101
+98,903
+575% +$1.39M 0.02% 848
2025
Q1 		$234K Sell
17,198
-36,160
-68% -$693K ﹤0.01% 1826
2024
Q4 		$1.09M Buy
+53,358
New +$1.37M 0.02% 958
2024
Q3 		– Sell
-11,130
Closed -$258K – 2183
2024
Q2 		$258K Sell
11,130
-20,226
-65% -$388K 0.01% 1541
2024
Q1 		$643K Buy
31,356
+18,684
+147% +$351K 0.02% 1062
2023
Q4 		$272K Sell
12,672
-10,937
-46% -$217K 0.01% 1507
2023
Q3 		$487K Sell
23,609
-8,211
-26% -$208K 0.02% 1077
2023
Q2 		$939K Sell
31,820
-24,965
-44% -$702K 0.04% 729
2023
Q1 		$1.31M Buy
+56,785
New +$1.56M 0.05% 477
2022
Q3 		– Sell
-17,320
Closed -$510K – 1721
2022
Q2 		$510K Buy
17,320
+1,274
+8% +$33.4K 0.02% 1101
2022
Q1 		$516K Buy
16,046
+10,356
+182% +$356K 0.02% 1049
2021
Q4 		$254K Buy
+5,690
New +$270K 0.01% 1507
2021
Q3 		– Sell
-6,030
Closed -$473K – 1718
2021
Q2 		$473K Sell
6,030
-8,550
-59% -$529K 0.03% 860
2021
Q1 		$833K Buy
14,580
+9,400
+181% +$629K 0.04% 670
2020
Q4 		$434K Sell
5,180
-2,876
-36% -$174K 0.02% 1060
2020
Q3 		$289K Buy
+8,056
New +$243K 0.01% 1269
2020
Q1 		– Sell
-12,793
Closed -$223K – 1650
2019
Q4 		$223K Buy
+12,793
New +$213K 0.01% 1419

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Engineers Gate Manager's DNLI Position: Q2 2026 in Review

Engineers Gate Manager increased its Denali Therapeutics (DNLI) stake by 256% in Q2 2026, buying an estimated $849K and bringing the position to 57,430 shares worth $1.48M. The position accounts for 0.02% of the portfolio, ranked #855.

Engineers Gate Manager first reported a position in DNLI in Q4 2019 and has held it in 20 quarters since. The position peaked at $1.62M in Q2 2025. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Engineers Gate Manager held 57,430 shares of Denali Therapeutics worth $1.48M as of Q2 2026.
  • Engineers Gate Manager bought 41,320 Denali Therapeutics shares in Q2 2026, an estimated $849K.
  • Denali Therapeutics made up 0.02% of Engineers Gate Manager's portfolio in Q2 2026, its #855 holding.
  • Engineers Gate Manager first reported a position in Denali Therapeutics in Q4 2019 and has held it in 20 quarters since.
  • Engineers Gate Manager's Denali Therapeutics position peaked at $1.62M in Q2 2025.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.